

platelets. A recombinant antispikes IgG (Cova1-18) cloned from a patient⁵ was modified to have usual glycosylation or low fucose (fuc) or high galactose (gal), or both. Only the low fuc/high gal IgG supported platelet accumulation over a von Willebrand factor (VWF)-coated surface in a flow chamber, at both venous and arterial shear rates. Bye et al decided to use the VWF-coated surface based on observations in vivo and ex vivo of high vWF on endothelial surfaces during COVID-19 infection. They show that prothrombotic platelet activation depends on interaction of the spike protein/Cova1-18 anti-SARS-CoV-2 IgG immune complex with FcγRIIIa, the sole Fcγ receptor on human platelets that is capable of mediating immunity and thrombosis.⁶ Additional evidence includes blockade of FcγRIIIA with the anti-FcγRIIIA ligand-blocking antibody IV.3 and reduction in activation with inhibitors to known platelet-signaling components downstream of FcγRIIIA (Syk, Btk, and P2Y12).

Together with a related study of anti-SARS-CoV-2 IgG stimulation of alveolar macrophages,⁴ Bye et al show that both FcγRIIIA and FcγRIIIA have increased avidity for the IgG Fc end that presents low-fuc/high-gal modifications. The result is increased effector functions, which in this case are prothrombotic. This paradigm is a new one for antibody-dependent inflammation contributing to prothrombotic effects (see figure). The new appreciation of the interactions of underfucosylated/overgalactosylated IgG with Fcγ receptors could advance the understanding and management of COVID-19, coagulopathies from other enveloped viruses, and other immune thrombotic thrombocytopenic disorders.

Conflict-of-interest disclosure: The author declares no competing financial interests. ■

REFERENCES

1. Bye A, Hoepel W, Mitchell J, et al. Aberrant glycosylation of anti-SARS-CoV-2 IgG is a prothrombotic stimulus for platelets. *Blood*. 2021;138(16):1481-1489.
2. Larsen MD, de Graaf EL, Sonneveld ME, et al; Biobank Study Group. Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity. *Science*. 2021;371(6532):eabc8378.
3. Chakraborty S, Gonzalez J, Edwards K, et al. Proinflammatory IgG Fc structures in patients

with severe COVID-19. *Nat Immunol*. 2021; 22(1):67-73.

4. Hoepel W, Chen HJ, Geyer CE, et al. High titers and low fucosylation of early human anti-SARS-CoV-2 IgG promote inflammation by alveolar macrophages. *Sci Transl Med*. 2021;13(596):eabf8654.
5. Brouwer PJM, Caniels TG, van der Straten K, et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets

of vulnerability. *Science*. 2020;369(6504): 643-650.

6. Patel P, Michael JV, Naik UP, McKenzie SE. Platelet FcγRIIIA in immunity and thrombosis: Adaptive immunothrombosis. *J Thromb Haemost*. 2021;19(5):1149-1160.

DOI 10.1182/blood.2021013359

© 2021 by The American Society of Hematology

RED CELLS, IRON, AND ERYTHROPOIESIS

Comment on Yanatori et al, page 1490

CD63 orchestrates ferritin export

Suzy V. Torti and Frank M. Torti | University of Connecticut Health Center

In this issue of *Blood*, Yanatori et al¹ demonstrate that the vesicular protein CD63 is regulated by iron and facilitates the secretion of iron-laden ferritin into extracellular vesicles, suggesting that CD63 may enable the transfer of iron-rich ferritin among cells.


Ferritin is a 24-subunit protein nanocage best known for its ability to store intracellular iron in a nontoxic but bioavailable form. A typical ferritin nanocage contains 1000 to 1500 atoms of iron and has the capacity to store >4000 atoms of iron, making it the principal intracellular iron reservoir and a critical contributor to the maintenance of intracellular iron homeostasis. However, ferritin is also found in extracellular compartments, notably human plasma. Levels of ferritin in plasma correlate with body iron stores and are also elevated in inflammation. Clinically, serum ferritin levels are used to assess iron status. The presence of ferritin in extracellular compartments has led to the suspicion that ferritin may play a role in extracellular as well as intracellular spaces, although the nature of that role and the mechanism by which ferritin reaches external environments have remained obscure for decades and are still incompletely understood.

A turning point in our understanding of extracellular ferritin came in 2018, when Truman-Rosentsvit et al² reported that ferritin can be secreted from macrophages through noncanonical pathways involving extracellular vesicles. However, what triggers ferritin secretion and how

it is coordinated with intracellular iron metabolism remained unclear.

Yanatori et al now demonstrate that increased iron levels increase expression of CD63, a tetraspanin protein and important constituent of extracellular vesicles. Mechanistically, CD63 induction is accomplished through an iron responsive element (IRE) in the 5' untranslated region of CD63 messenger RNA (mRNA) that is controlled by the same iron regulatory network that controls levels of ferritin itself. This network consists of iron regulatory proteins, which bind to IREs in the untranslated regions of selected mRNAs to posttranscriptionally control their activity or stability (see figure). Targets of the posttranscriptional iron regulatory network include not only ferritin but also proteins that regulate iron uptake and iron efflux, such as transferrin receptor 1 and ferroportin. Thus, the identification of a functional IRE in the 5' untranslated region of CD63 directly connects CD63 to pathways of iron metabolism.

The authors further show that the induction of CD63 by iron has a functional impact on iron metabolism by increasing the secretion of CD63⁺ extracellular vesicles containing iron-loaded ferritin. Mechanistically, iron loading stimulates



Export of ferritin-bound iron in CD63⁺ vesicles is enhanced by iron. (A) In an iron-poor cell, translation of CD63 as well as ferritin H and L subunits (represented in the figure as ferritin) is inhibited by iron regulatory proteins (IRPs). Iron-containing ferritin in the cell is directed by the cargo receptor NCOA4 to the lysosome for degradation, a process termed ferritinophagy.³ Ferritinophagy liberates iron contained within ferritin, enabling cellular use of iron for essential processes. (B) In an iron-replete cell, IRPs are inactivated, and translation of both CD63 and ferritin subunits is increased. Ferritin associates with NCOA4 and is directed to CD63⁺ vesicles by an unclear mechanism. CD63⁺ vesicles are shown in multivesicular bodies (MVBs) based on work by Truman-Rosentsvit et al² and Brown et al.⁴ Ferritin and its associated iron within CD63⁺ vesicles are ultimately exported out of the cell. Professional illustration by Patrick Lane, ScEYence Studios.

the association of ferritin and its cargo receptor NCOA4 with CD63⁺ vesicles, facilitating extracellular release of ferritin. Under iron-poor conditions, NCOA4 mediates ferritin degradation to release iron and rebalance intracellular labile iron pools in a process termed ferritinophagy.³ The authors now show that NCOA4 can also mediate ferritin secretion under iron-rich conditions. The mechanism underlying the iron-dependent switch in NCOA4-mediated ferritin trafficking remains unknown. Removal of ferritin-bound iron through CD63⁺ vesicles is an additional pathway for iron exit from cells that complements the activity of ferroportin, a well-described iron efflux pump that transports elemental iron.

Collectively, these data are consistent with a model in which induction of CD63 by iron promotes iron removal through secretion of iron-laden ferritin in extracellular vesicles. The authors perform their studies primarily in transformed human fibroblasts and confirm their results in other cell lines, including hepatocellular

carcinoma cells and monocytes (HepG2, THP1). This suggests that CD63-mediated secretion of ferritin by extracellular vesicles may be a general pathway of iron export. However, only transformed cells were examined, so further confirmation of this pathway is necessary. This work is consistent with evidence that secretion of ferritin in extracellular vesicles by breast cancer cells reduces their sensitivity to ferroptosis, an iron-dependent form of cell death.⁴

Mysteries remain. Yanatori et al show that iron promotes the secretion of iron-laden ferritin in extracellular vesicles. What happens to this ferritin and to the iron it contains? One attractive possibility is that it serves as an iron source for neighboring cells, perhaps through binding to ferritin receptors^{5,6} and catabolism through ferritinophagy. If so, what prevents a futile cycle of ferritin-bound iron secretion and uptake by the same cell? One speculative answer is that in addition to stimulating CD63-dependent secretion of ferritin, iron repletion also discourages uptake of extracellular

vesicles, thus redirecting ferritin-bound iron to adjacent, potentially more iron-deficient, neighboring cells. Using radioactive or other tracers to follow the path of both iron and ferritin might be useful in addressing such questions, as would studying this pathway in tissue environments containing multiple cell types.

Another mystery: what is the connection, if any, between ferritin found in extracellular vesicles and serum ferritin? Despite its positive correlation with body iron stores, ferritin found in plasma is notably iron poor⁷ and therefore different from the iron-rich ferritin identified by Yanatori et al in extracellular vesicles. Do these 2 pools of extracellular ferritin represent separate entities? Or are they produced by the same pathway, but with differing iron content based on the iron status or ferritin subunit composition of the producing cell? Alternatively, is iron-rich ferritin taken up by cells, leaving only its iron-poor relative in the plasma, or is the iron somehow removed from iron-containing ferritin in extracellular vesicles

to produce iron-poor serum ferritin? If iron is removed from ferritin, how is this accomplished? Because known pathways of iron removal from ferritin such as ferritinophagy result in degradation of the ferritin protein, they do not offer a plausible mechanism for the generation of iron-poor ferritin in the plasma from iron-rich ferritin in extracellular vesicles. Likely, there are more pathways of ferritin and iron trafficking yet to be discovered.

Conflict-of-interest disclosure: The authors declare no competing financial interests. ■

REFERENCES

1. Yanatori IR, Richardson DR, Dhekne HS, Toyokuni S, Kishi F. CD63 is regulated by iron via the IRE-IRP system and is important for ferritin secretion by extracellular vesicles. *Blood*. 2021;138(16):1490-1503.
2. Truman-Rosentsvit M, Berenbaum D, Spektor L, et al. Ferritin is secreted via 2 distinct nonclassical vesicular pathways. *Blood*. 2018; 131(3):342-352.
3. Mancias JD, Wang X, Gygi SP, Harper JW, Kimmelman AC. Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy. *Nature*. 2014; 509(7498):105-109.
4. Brown CW, Amante JJ, Chhoy P, et al. Prominin2 drives ferroptosis resistance by stimulating iron export. *Dev Cell*. 2019;51(5): 575-586.e4.
5. Han J, Seaman WE, Di X, et al. Iron uptake mediated by binding of H-ferritin to the TIM-2 receptor in mouse cells. *PLoS One*. 2011; 6(8):e23800.
6. Li L, Fang CJ, Ryan JC, et al. Binding and uptake of H-ferritin are mediated by human transferrin receptor-1. *Proc Natl Acad Sci USA*. 2010;107(8):3505-3510.
7. Wang W, Knovich MA, Coffman LG, Torti FM, Torti SV. Serum ferritin: past, present and future. *Biochim Biophys Acta*. 2010;1800(8):760-769.

DOI 10.1182/blood.2021013181

© 2021 by The American Society of Hematology